European Patent for Teva’s Copaxone Upheld by UK Court

Yeda, the Tech Transfer Company of the Weizmann Institute has a patent for glatiramer acetate which is exclusively licensed to Teva. The pharmaceutical is marketed as Copaxone and used to treat multiple schlerosis (MS).

Mylan challenged the validity of the European patent EP 07862888  which, after a 13 day trial has been upheld by Mr Justice Arnold (Patents Court, England and Wales) in Generics (t/a Mylan) v Yeda and Teva [2012] EWHC 1848 (Pat).

For more details on this development, I refer readers to the IPKAT here.

We note that the US patent was recently upheld – see our previous post here for more details.

 



Categories: drugs, EPO, Intellectual Property, Israel IP, Israel Patent, Israel Related, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva, Uncategorized

1 reply

Trackbacks

  1. Pharma & Biotech Global Week in Review 18 July 2012 from IP Think Tank | Duncan Bucknell

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: